- Let's make a deal April 22
Two of the world's biggest drugmakers, Britain's GlaxoSmithKline and Switzerland's Novartis, announced a complex hodgepodge of deals worth at least $25 billion on Tuesday. The main components:
* Novartis agreed to buy Glaxo's oncology business for between $14.5 billion and $16 billion
* Glaxo is buying Novartis' vaccine business for between $5.3 billion and $7.1 billion
* The two companies are combining their consumer health (over-the-counter) divisions, with Glaxo taking 63.5 percent of the joint venture
* Eli Lilly will purchase Novartis' animal health unit for about $5.4 billion
The transactions will let Novartis focus on high-margin businesses like cancer drugs while Glaxo boosts its position in consumer goods and the low-margin, high-volume vaccine market. But the pharmaceutical giants aren't the only drugmakers making high-stakes deals. The Wall Street Journal says the $25 billion worth of transactions cap a 24-hour period where "deals worth, conservatively, $65 billion" were announced, not counting Pfizer's unsolicited $101 billion offer to buy Britain's AstraZeneca.
"The Novartis-Glaxo deal and rumors about a potential AstraZeneca acquisition by Pfizer are giving the pharma sector a decent run this morning," Danish strategist Witold Bahrke tells Bloomberg News. "It's also fueling further M&A expectations."- -
THE WEEK'S AUDIOPHILE PODCASTS: LISTEN SMARTER
- The U.S. is about to sell weapons to Vietnam. That's bad news for China.
- Why is the Pentagon stuffing caves in Norway full of tanks?
- What the Middle Ages can tell us about the GOP's big charity myth
- An open letter to #brands about Gamergate
- 43 TV shows to watch in 2014
- Did the media get Ferguson wrong?
- The most sensible GOP alternative to ObamaCare comes from a Senate candidate who is almost sure to lose
- Painting the universe's portrait
- 'Having it all' has officially jumped the shark
- How to be the most productive person in your office — and still get home by 5:30 p.m.
Subscribe to the Week